Humacyte, Inc. (HUMA) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

13/25

Growth 3 Margin 2 Expansion 3 Platform 3 Financial 2

latest quarter score

Earnings Reports

13
Humacyte (HUMA) Q2 2026: 91 More Catheter-Free Days in Dialysis Trial Signals Major Clinical Breakthrough
August 12, 2026
11
Humacyte (HUMA) Q1 2026: 25% Workforce Cut Unlocks $14.3M in Cost Savings as Commercial Pivot Accelerates
May 13, 2026
12
Humacyte (HUMA) Q4 2025: VAC Approval Rate Tops 70% as Symbeth Adoption Broadens
March 27, 2026
11
Humacyte (HUMA) Q3 2025: SimVest Revenue Jumps 7x as Hospital Adoption Accelerates
November 12, 2025
9
Humacyte (HUMA) Q2 2025: Hospital Access Expands 16x as SimVest Pricing Reset Drives Uptick
August 11, 2025
10
Humacyte (HUMA) Q1 2025: 45 Hospital Evaluations Signal SimVest Launch Momentum
July 06, 2025
8
Humacyte (HUMA) Q4 2024: Symvess Launch Accelerates with 34 Hospitals Engaged in VAC Process
March 28, 2025

Browse all companies